Yet More Data on Psychedelics in Veterans with Depression
And it's early, but it's good.
Greetings from Seattle! I am writing a column that is not very child psychiatry-focused today because I could write it quickly. That is how much I care, dear readers, to feed your almost unquenchable hunger for health-themed journalism. This is The Frontier Psychiatrists, live from AACAP 2024. Now, today’s column.
Contra the claims of Midofedamine evangelicals, claiming that MDMA-AT was desperately needed because, as Nutt Et. Al. Argued in an editorial published on October 10th:
there has been an urgent need for innovation in the treatment of PTSD for decades1
As if there had not been innovation (a falsehood, given the other innovative treatments that have been demonstrated at various stages of development):
the FDA held a public advisory committee (AdCom) hearing in early June 2024. This committee almost unanimously rejected both the evidence of efficacy and the benefit–risk profile for MDMA-assisted therapy (MDMA-AT) submitt…